Navigation Links
BUSM researchers identify novel approach to study COPD and treatment efficacy
Date:4/11/2013

(Boston) Researchers from Boston University School of Medicine (BUSM) have pinpointed a genetic signature for chronic obstructive pulmonary disease (COPD) from airway cells harvested utilizing a minimally invasive procedure. The findings provide a novel way to study COPD and could lead to new treatments and ways to monitor patient's response to those treatments. The study is published online in the American Journal of Respiratory and Critical Care Medicine.

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that leads to the loss of lung function primarily caused by cigarette smoking. It causes coughing, wheezing, shortness of breath, chest tightness and other symptoms that make it difficult to breathe. While there are treatments and lifestyle changes that can help people cope with COPD, there currently is no cure and there are no effective therapies to reduce the rate of lung function decline. According to the National Institutes of Health's National Heart, Lung, and Blood Institute (NHLBI), which partially funded the study, COPD is the third leading cause of death in the United States, resulting in approximately 135,000 deaths each year.

"There have been limited molecular studies of COPD given the inaccessibility and invasiveness of obtaining lung tissue," said Katrina Steiling, MD, MSc, assistant professor of medicine at BUSM who served as the study's first author. The researchers hypothesized that while COPD primarily affects the tissue deep within the lung, the effects of COPD might be detectable in relatively accessible tissue throughout the respiratory tract. This echoes previous work they had done that found that cancer found deep in the lung could be detected by cancer-specific patterns of gene expression in the largest airways connected to the windpipe, far from the tumor.

To examine their hypothesis, the research team used airway cells obtained during a bronchoscopy, a procedure that involv
'/>"/>

Contact: Jenny Eriksen
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Researchers call for marine observation network
2. Biofilms help Salmonella survive hostile conditions, Virginia Tech researchers say
3. U-M researchers find new way to clear cholesterol from the blood
4. Dartmouth researchers find there is no single sexy chin
5. Researchers design drug to restore cell suicide in HPV-related head and neck cancer
6. Researchers shine light on how stress circuits learn
7. Cleveland Clinic researchers discover new link between heart disease and red meat
8. SFU researchers help unlock pine beetles Pandoras box
9. Empa researchers join Quantis to open new branch in Switzerland
10. MDC and FMP researchers identify edema inhibitor
11. Barrow researchers identify
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/10/2015)... , March 10, 2015  Continuing its 167-year ... Unexpected, Hammacher Schlemmer introduces The Eye Scanning Password ... before granting access to secure websites or sensitive data. ... verify travelers at international borders, the device has a ... pattern points of the iris, converting them into an ...
(Date:3/10/2015)...   Tute Genomics , pioneer in affordable, accurate ... sequencing company PrimBio Research Institute to be ... panel interpretation. PrimBio, a certified Life Technologies ... technologies to support the work of experts on the ... types of exome sequencing services: 1) Targeted Exome and ...
(Date:3/5/2015)... In Brazil , cloud computing ... these solutions and 42 percent planning to invest in them ... percent of the companies will be investing in these solutions ... companies in the region are currently opting for the private ... command significant attention in the coming years. This trend is ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... In an international human genetic study, researchers at UT Southwestern ... disease lupus, and its location on the X chromosome might ... the disease than males. Identifying this gene, IRAK1, as ... Chandra Mohan, professor of internal medicine and senior author of ...
... nervous system or brain. So how do individual bacterial ... a biofilm "decide" between different physiological processes (such as ... In the prestigious 2009 Fleming lecture, given ... (Monday 30 March) Dr Nicola Stanley-Wall from the University ...
... coastal mudflats have an essential role to play in ... by Dr Efe Aganbi and colleagues from the University ... meeting at Harrogate today (Monday 30 April), reveals essential ... depending on whether or not oxygen is present. In ...
Cached Biology News:Gene linked to lupus might explain gender difference in disease risk 2Microbes in mud flats clean up oil spill chemicals 2
(Date:3/30/2015)... , March 30, 2015  Heidrick & Struggles (Nasdaq: ... leadership consulting and culture shaping worldwide, ... firm to lead its global Healthcare and Life Sciences practice. ... Life Sciences, Mitchell will lead a team of more than ... Europe and Asia serving ...
(Date:3/30/2015)... , March 30, 2015 US-Australian drug ... and its subsidiary, CanTx, Inc., and Yale University, on ... Cantrixil. The data was presented as an oral presentation ... Yale Medical School to the 62 nd Annual ... San Francisco, CA. ...
(Date:3/30/2015)... , March 30, 2015    Intrexon ... in synthetic biology, and Merck Serono, the biopharmaceutical ... , today announced an exclusive strategic collaboration ... Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration ... innovative therapies that modulate the immune system,s natural ...
(Date:3/30/2015)... 30, 2015 Immunocore Limited, ... to treat cancer, viral infections and autoimmune disease, ... John Bell , the Regius Professor of Medicine ... for the Strategic Coordination of Health Research, to ...      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ) , ...
Breaking Biology Technology:Heidrick & Struggles Strengthens Leadership of Healthcare - Life Sciences Practice 2Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5
... Pharmaceuticals today announced,the initiation of a Phase II ... tumors (C/NET), which are malignant,cancers arising from neural ... "Quarfloxin (CX-3543) is a small molecule that ... nucleoli of cancer cells, thereby,selectively inducing apoptotic cell ...
... with any rigor if the subject can,t be ... carbon nanotubes -- nanomaterials with promising technological applications ... The problem is that current techniques for synthesizing ... multi-walled nanotubes. These two forms each have interesting ...
... Calif., Dec. 12 Bionovo, Inc.,(Nasdaq: BNVI ) ... agent BN107 at the 31st Annual San Antonio Breast Cancer ... Antonio TX,December 10-14, 2008. , ... cell,apoptosis (cell death) induced by BN107. As explained by Dr. ...
Cached Biology Technology:Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 2Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors 3Method sorts out double-walled carbon nanotube problem 2Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium 2
Agarose Gel Loading Dye Mixture 6X...
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Biology Products: